Christina Yau

Christina Yau, PhD is a Professor of Surgery at the University of California, San Francisco (UCSF) School of Medicine, where she leads groundbreaking research in breast cancer translational science. With a PhD in Bioengineering from UCSF (2007), she has established herself as a key contributor to the I-SPY clinical trials program, which is revolutionizing neoadjuvant therapy development for breast cancer.

Education:

• PhD in Bioengineering, University of California, San Francisco (2007)

Dr. Yau's research spans multiple critical areas of breast cancer translational research with a particular emphasis on neoadjuvant therapy response prediction. Her work integrates genomic analysis, circulating tumor DNA, and advanced imaging techniques to develop personalized treatment approaches. Key research interests include breast cancer biomarker discovery, neoadjuvant therapy response prediction, genomic analysis of treatment resistance, circulating tumor DNA as a biomarker, adaptive clinical trial design, and personalized medicine approaches in breast cancer. Her innovative approach has positioned her at the forefront of precision oncology.

Analysis of Dr. Yau's extensive publication record (over 100 papers since 2012) reveals a consistent focus on the I-SPY clinical trial program, which aims to accelerate drug development in breast cancer through adaptive trial design. Her work demonstrates how genomic signatures, imaging biomarkers, and circulating tumor DNA can predict treatment response and guide therapeutic decisions. This research has significant implications for moving toward more personalized, effective breast cancer treatment strategies and has contributed substantially to our understanding of treatment resistance mechanisms.

Dr. Yau has been instrumental in several major clinical trials, particularly the I-SPY series, which have transformed how we approach neoadjuvant therapy in breast cancer. Her collaborative approach bridges basic science, translational research, and clinical application, working closely with leading researchers including Laura Esserman. Her contributions to the field have been recognized through numerous high-impact publications in journals including Nature, Cancer Cell, and JAMA Oncology.